MarketInOut Stock Screener Log In | Sign Up
 

Virax Biolabs Group Ltd

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Virax Biolabs Group Ltd stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1.66 mln
Float1.34 mln
Earnings Date11/30/2026

Piotroski F-Score

6 / 9
Solid

Relative Strength

5 / 100
Severely lagging

Debt / Equity

0.06
Debt-free

Pre-Tax Margin

-47,754%
Severely loss-making

ROE

-81.09
Deeply negative

Altman Z-Score

-4.6
Deeply distressed

Business Description

Virax Biolabs Group Limited is a UK-based biotechnology company that develops and sells diagnostic test kits for detecting and managing viral diseases, covering areas such as respiratory illness, infectious diseases, fertility, cancer, and animal health. The company also offers a T cell diagnostic device paired with a wellness app, along with laboratory services including antibody engineering, vaccine testing, and custom protein work. It serves hospitals, research organizations, independent labs, and distributors across the United Kingdom, the United States, and China.

Key Fundamentals

EPS-12.64
ROE-81.09
RPS0.03
ROIC-260
ROA-73.64
Interest Cover-96.86
EBITDA, mln-5.43
EV / EBITDA0.61
EV / EBIT0.57
Revenue, mln0.01

Quote Details

Last 1.22
Change -0.02 (-1.61%)
Open 1.24
Volume 33,609
Turnover 41,003
Average Volume 191,602

Financial Ratios

Pre-Tax Profit Margin-47,754
Leverage Ratio1.10
Current Ratio9.97
Price / Book0.17
Price / Tangible Book0.17
Debt / Equity0.06
Price / Sales81.12

Financial Strength

Altman Z-Score-4.6
Piotroski F-Score 6 / 9
Short Ratio0.19
Short % of Float0.50

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -15.86% 5 / 100   
1 Month -50% 4 / 100   
2 Months -68.64% 4 / 100   
6 Months -69.42% 7 / 100   
1 Year -91.96% 5 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog